AIM Key Statistics, Chart & Performance
The current stock price of AIM is 1.39 USD. In the past month the price decreased by -30.85%. In the past year, price increased by 396.43%.
AIM Latest News, Press Relases and Analysis
AIM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.55B | ||
| AMGN | AMGEN INC | 15.47 | 182.20B | ||
| GILD | GILEAD SCIENCES INC | 15.13 | 153.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.95 | 109.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.49 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 911.63 | 61.42B | ||
| INSM | INSMED INC | N/A | 44.06B | ||
| NTRA | NATERA INC | N/A | 32.66B | ||
| BIIB | BIOGEN INC | 10.76 | 26.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.97 | 20.42B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About AIM
Company Profile
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 21 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Company Info
AIM IMMUNOTECH INC
2117 Sw Highway 484
Ocala FLORIDA 34473 US
CEO: Thomas K. Equels
Employees: 21
Phone: 13524487797
AIM IMMUNOTECH INC / AIM FAQ
What does AIM IMMUNOTECH INC do?
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 21 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
What is the stock price of AIM IMMUNOTECH INC today?
The current stock price of AIM is 1.39 USD. The price decreased by -10.32% in the last trading session.
What is the dividend status of AIM IMMUNOTECH INC?
AIM does not pay a dividend.
How is the ChartMill rating for AIM IMMUNOTECH INC?
AIM has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is AIM IMMUNOTECH INC (AIM) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AIM.
Can you provide the number of employees for AIM IMMUNOTECH INC?
AIM IMMUNOTECH INC (AIM) currently has 21 employees.
When does AIM IMMUNOTECH INC (AIM) report earnings?
AIM IMMUNOTECH INC (AIM) will report earnings on 2026-03-30, after the market close.
AIM Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to AIM. When comparing the yearly performance of all stocks, AIM is one of the better performing stocks in the market, outperforming 98.93% of all stocks.
AIM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AIM. AIM has a bad profitability rating. Also its financial health evaluation is rather negative.
AIM Financial Highlights
Over the last trailing twelve months AIM reported a non-GAAP Earnings per Share(EPS) of -20.25. The EPS decreased by -87.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -391.52% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AIM Forecast & Estimates
5 analysts have analysed AIM and the average price target is 24.48 USD. This implies a price increase of 1661.15% is expected in the next year compared to the current price of 1.39.
For the next year, analysts expect an EPS growth of 66.48% and a revenue growth -51.38% for AIM